Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2008 1
2009 5
2011 2
2012 2
2013 4
2014 2
2015 4
2016 5
2017 5
2018 5
2019 2
2020 7
2021 5
2022 1
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

44 results

Results by year

Filters applied: . Clear all
Page 1
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial.
Guigay J, Aupérin A, Fayette J, Saada-Bouzid E, Lafond C, Taberna M, Geoffrois L, Martin L, Capitain O, Cupissol D, Castanie H, Vansteene D, Schafhausen P, Johnson A, Even C, Sire C, Duplomb S, Evrard C, Delord JP, Laguerre B, Zanetta S, Chevassus-Clément C, Fraslin A, Louat F, Sinigaglia L, Keilholz U, Bourhis J, Mesia R; GORTEC; AIO; TTCC, and UniCancer Head and Neck groups. Guigay J, et al. Lancet Oncol. 2021 Apr;22(4):463-475. doi: 10.1016/S1470-2045(20)30755-5. Epub 2021 Mar 5. Lancet Oncol. 2021. PMID: 33684370 Clinical Trial.
6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial.
Pivot X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T, Lortholary A, Espié M, Fumoleau P, Serin D, Jacquin JP, Jouannaud C, Rios M, Abadie-Lacourtoisie S, Venat-Bouvet L, Cany L, Catala S, Khayat D, Gambotti L, Pauporté I, Faure-Mercier C, Paget-Bailly S, Henriques J, Grouin JM; PHARE trial investigators. Pivot X, et al. Lancet. 2019 Jun 29;393(10191):2591-2598. doi: 10.1016/S0140-6736(19)30653-1. Epub 2019 Jun 6. Lancet. 2019. PMID: 31178155 Clinical Trial.
Effects of a physical activity programme to prevent physical performance decline in onco-geriatric patients: a randomized multicentre trial.
Arrieta H, Astrugue C, Regueme S, Durrieu J, Maillard A, Rieger A, Terrebonne E, Laurent C, Maget B, Servent V, Lavau-Denès S, Dauba J, Fonck M, Thiébaut R, Bourdel-Marchasson I. Arrieta H, et al. Among authors: lavau denes s. J Cachexia Sarcopenia Muscle. 2019 Apr;10(2):287-297. doi: 10.1002/jcsm.12382. Epub 2019 Mar 4. J Cachexia Sarcopenia Muscle. 2019. PMID: 30829460 Free PMC article. Clinical Trial.
Comparison of 18FDG-PET/CT and conventional follow-up methods in colorectal cancer: A randomised prospective study.
Monteil J, Le Brun-Ly V, Cachin F, Zasadny X, Seitz JF, Mundler O, Selvy M, Smith D, Rullier E, Lavau-Denes S, Lades G, Labrunie A, Lecaille C, Valli N, Leobon S, Terrebonne E, Deluche E, Tubiana-Mathieu N. Monteil J, et al. Among authors: lavau denes s. Dig Liver Dis. 2021 Feb;53(2):231-237. doi: 10.1016/j.dld.2020.10.012. Epub 2020 Nov 2. Dig Liver Dis. 2021. PMID: 33153929 Free article. Clinical Trial.
Panel gene profiling of small bowel adenocarcinoma: Results from the NADEGE prospective cohort.
Aparicio T, Svrcek M, Henriques J, Afchain P, Lièvre A, Tougeron D, Gagniere J, Terrebonne E, Piessen G, Legoux JL, Lecaille C, Pocard M, Gornet JM, Zaanan A, Lavau-Denes S, Lecomte T, Deutsch D, Vernerey D, Puig PL. Aparicio T, et al. Among authors: lavau denes s. Int J Cancer. 2021 Apr 1;148(7):1731-1742. doi: 10.1002/ijc.33392. Epub 2021 Jan 4. Int J Cancer. 2021. PMID: 33186471 Free article.
Small bowel adenocarcinoma: Results from a nationwide prospective ARCAD-NADEGE cohort study of 347 patients.
Aparicio T, Henriques J, Manfredi S, Tougeron D, Bouché O, Pezet D, Piessen G, Coriat R, Zaanan A, Legoux JL, Terrebone E, Pocard M, Gornet JM, Lecomte T, Lombard-Bohas C, Perrier H, Lecaille C, Lavau-Denes S, Vernerey D, Afchain P; NADEGE Investigators. Aparicio T, et al. Among authors: lavau denes s. Int J Cancer. 2020 Aug 15;147(4):967-977. doi: 10.1002/ijc.32860. Epub 2020 Jan 22. Int J Cancer. 2020. PMID: 31912484
Incidence and associated factors of cetuximab-induced hypersensitivity infusion reactions in 1392 cancer patients treated in four French areas: a possible association with Lyme disease?
Dupont M, Carlier C, Gower-Rousseau C, Barbier-Lider P, Botsen D, Brasseur M, Burgevin A, Chourbagi C, D'Almeida R, Hautefeuille V, Hentzien M, Lambert A, Lamuraglia M, Lavau-Denes S, Lopez A, Parent D, Slimano F, Brugel M, Bouché O. Dupont M, et al. Among authors: lavau denes s. BMC Cancer. 2022 Nov 25;22(1):1219. doi: 10.1186/s12885-022-10192-4. BMC Cancer. 2022. PMID: 36434607 Free PMC article.
Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.
BIG 1-98 Collaborative Group; Mouridsen H, Giobbie-Hurder A, Goldhirsch A, Thürlimann B, Paridaens R, Smith I, Mauriac L, Forbes J, Price KN, Regan MM, Gelber RD, Coates AS. BIG 1-98 Collaborative Group, et al. N Engl J Med. 2009 Aug 20;361(8):766-76. doi: 10.1056/NEJMoa0810818. N Engl J Med. 2009. PMID: 19692688 Free PMC article. Clinical Trial.
Protein intake, weight loss, dietary intervention, and worsening of quality of life in older patients during chemotherapy for cancer.
Regueme SC, Echeverria I, Monéger N, Durrieu J, Becerro-Hallard M, Duc S, Lafargue A, Mertens C, Laksir H, Ceccaldi J, Lavau-Denes S, Dantoine T, Irazusta J, Bourdel-Marchasson I. Regueme SC, et al. Among authors: lavau denes s. Support Care Cancer. 2021 Feb;29(2):687-696. doi: 10.1007/s00520-020-05528-4. Epub 2020 May 20. Support Care Cancer. 2021. PMID: 32435967 Clinical Trial.
44 results